NCT01075191

Kaletra: Therapy With Double Protease Inhibitors

PMOS: Kaletra Double Protease Inhibitors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 65 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants

Detailed description

This study is intended to observe and collect data on the usage, dosing, tolerability, and effectiveness of lopinavir/ritonavir (Kaletra) when used as part of a Nucleoside Reverse Transcriptase Inhibitors-free double protease regimen. Enrollment in the study was independent of the decision to prescribe Kaletra.

Conditions

• Human Immunodeficiency Virus

Timeline

• Start date: 2004-01-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-02-25
• Last updated: 2013-01-18
• Results posted: 2012-10-30

Locations

17 sites across 1 country: Germany